The liver can't convert more than 3 iu's at a time?  

Page 2 / 2
  RSS

oswaldosalcedo
(@oswaldosalcedo)
Trusted Member
Joined: 9 months ago
Posts: 74
08/05/2019 8:13 pm  

i post this one:

Clin Endocrinol (Oxf). 2005 Apr;62(4):449-57.
Supraphysiological growth hormone: less fat, more extracellular fluid but uncertain effects on muscles in healthy, active young adults.

Ehrnborg C, Ellegard L, Bosaeus I, Bengtsson BA, Rosen T.

Research Centre for Endocrinology and Metabolism, Department of Internal Medicine, Sahlgrenska University Hospital, S-413 45 Goteborg, Sweden.

"OBJECTIVES: To study the effects on body composition after 1 month's administration of supraphysiological doses of growth hormone (GH) in healthy, active young adults with normal GH-IGF-I axis. SUBJECTS AND METHODS: Thirty healthy, physically active volunteers (15 men and 15 women), mean age 25.9 years (range 18-35), participated in this study, designed as a randomized, double-blind, placebo-controlled, parallel study with three groups (n = 10: five men and five women in each group). The groups comprised the following: placebo (P), GH 0.1 IU/kg/day [0.033 mg/kg/day] (GH 0.1) and GH 0.2 IU/kg/day [0.067 mg/kg/day] (GH 0.2). RESULTS: In the pooled group with active GH treatment (n = 20) the results showed significant increases: IGF-I increased by 134% (baseline vs. after 1 month), body weight by 2.7%, fat free mass by 5.3%, total body water by 6.5% and extracellular water (ECW) by 9.6%. Body fat decreased significantly by 6.6%. No significant change in intracellular water was detected. The observed increase in fat free mass by 5.3% was explained by the ECW increase, indicating limited anabolic effects of the supraphysiological GH doses. Changes were noticeable in both genders, although more prominent in the male subjects. Fluid retention symptoms occurred in the majority of individuals. CONCLUSIONS: This is, to our knowledge, the first placebo-controlled trial to show the effects of supraphysiological GH doses on body composition and IGF-I levels in physically active and healthy individuals of both genders; the results indicate limited anabolic effects of GH with these supraphysiological doses. The role of GH as an effective anabolic doping agent is questioned."

and this:

The Journal of Clinical Endocrinology & Metabolism 2003 Vol. 88, No. 11 5221-5226 , by The Endocrine Society.
"High Dose Growth Hormone Exerts an Anabolic Effect at Rest and during Exercise in Endurance-Trained Athletes
M. L. Healy, J. Gibney, D. L. Russell-Jones, C. Pentecost, P. Croos, P. H. Sönksen and A. M. Umpleby
Department of Diabetes and Endocrinology, GKT School of Medicine, St. Thomas Hospital, London, United

r-hGH-treated

-------------------- Baseline --------- 1wk-----------4 wk--------- /Placebo-

IGF-I (nmol/liter) 24.6 ± 3.0 / 89.6 ± 12.21-- 106.3 ± 16.41/ 25.8 ± 2.7-- 25.4 ± 2.7-- 25.2 ± 2.6
f t3 (pmol/liter) 5.1 ± 0.3 6.0 ± 0.12 6.1 ± 0.22 4.8 ± 0.2 4.9 ± 0.2 4.8 ± 0.1
fT4 (pmol/liter) 15.5 ± 1.5 11.5 ± 1.02 10.6 ± 0.92 15.8 ± 1.6 15.6 ± 1.7 15.8 ± 1.5
Testosterone(nmol/liter) 18.3 ± 3.2 18.5 ± 3.4 18.5 ± 3.3 16.7 ± 2.6 16.3 ± 2.6 16.4 ± 2.2
Glucose (mmol/liter) 4.7 ± 0.3 5.5 ± 0.5 5.3 ± 0.2 4.5 ± 0.4 4.2 ± 0.2 4.4 ± 0.3
Insulin (mU/liter) 7.9 ± 1.6 22.6 ± 3.92 16.0 ± 9.32 6.0 ± 0.3 5.6 ± 1.9 9.3 ± 2.4
HOMA IR 1.4 ± 0.2 5.1 ± 1.02 3.3 ± 0.62 1.1 ± 0.4 1.0 ± 0.3 1.6 ± 0.5
Total cholesterol (mmol/liter) 4.3 ± 0.3 4.0 ± 0.5 4.1 ± 0.3 3.4 ± 0.3 3.3 ± 0.3 3.5 ± 0.6
Triglyceride 1.1 ± 0.2 2.0 ± 0.5 1.3 ± 0.1 0.6 ± 0.1 0.7 ± 0.1 0.5 ± 0.1
LDL cholesterol (mmol/liter) 2.6 ± 0.3 2.2 ± 0.3 2.3 ± 0.3 1.6 ± 0.4 1.6 ± 0.3 1.6 ± 0.5
HDL cholesterol (mmol/liter) 1.2 ± 0.1 1.0 ± 0.1 1.1 ± 0.1 1.5 ± 0.1 1.5 ± 0.1 1.7 ± 0.2
Body weight (kg) 74.4 ± 1.1 76.5 ± 1.72 77.9 ± 1.62 74.9 ± 3.4 74.9 ± 3.4 74.7 ± 3.3
Lean body mass (kg) 57.6 ± 1.1 61.0 ± 1.22 61.6 ± 2.5 61.8 ± 2.4
Total body fat (kg) 11.4 ± 1.4 11.6 ± 1.7 9.8 ± 1.9 10.1 ± 2.0
Trunk fat (kg) 4.7 ± 0.7 4.5 ± 0.9 2.8 ± 0.9 2.8 ± 0.9

There was no change in IGF-I levels in the placebo-treated group throughout the observation period. In contrast, in the r-hGH-treated group, IGF-I levels rose markedly, reaching levels outside the physiological range (P < 0.001; Table 2 ). These changes occurred within 7 d of commencing r-hGH administration and did not change further over the remaining 21-d period of r-hGH administration.

there is difference according HGH doses.

if somebody wish, i can post more,to demostrate it more clearly.

dr frankenstein


ReplyQuote
Clarityandfocus
(@clarityandfocus)
Eminent Member
Joined: 11 months ago
Posts: 21
08/05/2019 8:55 pm  

I don't know about all those studies...

What I do know is that accelerating the metabolism (t-3, for example) will increase the liver's capacity to manufacture the many, varied growth factors.

Clarity


ReplyQuote
oswaldosalcedo
(@oswaldosalcedo)
Trusted Member
Joined: 9 months ago
Posts: 74
08/05/2019 9:35 pm  

correct!
the liver manufacture that growth factors.

dr frankenstein


ReplyQuote
Clarityandfocus
(@clarityandfocus)
Eminent Member
Joined: 11 months ago
Posts: 21
09/05/2019 7:30 am  
Posted by: oswaldosalcedo
correct!
the liver manufacture that growth factors.

Yeah, I intentionally chose the term "manufacture." Helping the liver "create" growth factors from their substrates is crucial.

Artifically accelerating the metabolism when administering supraphysiological levels of hormones only makes sense for maximum efficacy. Methylated oral compounds come to mind.

I view GH as a precursor to better things, although it does a lot of beneficial things intact.

Clarity


ReplyQuote
Page 2 / 2
Share:
  
Working

Please Login or Register